SANTA ANA, Calif., July 10, 2025 – NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the administration of the first dose of troculeucel, an expanded autologous NK cell therapy, under a single […] The post NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who...
